酒精性肝病的发病机制和药物干预研究新进展OA

Alcoholic liver disease(ALD)is a dis-ease of the liver that results from prolonged and heavy drinking,which is initially manifested as a fat-ty liver,and then develops into hepatitis,cirrhosis,and even hepatocellular carcinoma.The pathogene-sis of ALD is characterized by oxidative stress,im-mune inflammation,gut-hepatic axis,apoptosis,and autophagy induced by regulatory factors such as acetaldehyde dehydrogenase 2(ALDH2),nuclear factor-κB(NF-κB),and farnesol X receptor(FXR).This article takes regulatory factors as the entry point to summarize drugs such as the NF-κB in-hibitor ergacurone,the FXR agonist INT-787,and the PPARα agonist fenofibrate,and explores the current research status from broad treatment to targeted precision treatment.The aim is to gain a deeper understanding of the pathogenesis of ALD and provide a basic information for the prevention and control research of ALD and targeted drug in-tervention.